Aegerion (AEGR) Trading Halted Ahead of Lomitapide FDA Committee Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Jefferies Boosts Price Target on Aegerion (AEGR) after Positive FDA Panel
October 18, 2012 3:33 PM EDTJefferies raised its price target on Aegerion Pharmaceuticals (NASDAQ: AEGR) from $20 to $22 after FDA panel backing.
"FDA's panel voted 13-2 for recommending approval of lomitapide. Focus now is on the # of eligible patient population & commercial opportunity. Panel discussion did not clearly define #... More
Needham & Company Raises Aegerion Pharmaceuticals (AEGR) Price Target to $30
October 18, 2012 10:19 AM EDTNeedham & Company boosted its price target on Buy-rated Aegerion Pharmaceuticals (NASDAQ: AEGR) from $22 to $30 after an FDA panel backed Lomitapide.
"Yesterday, an FDA Advisory Committee voted 13-2 in favor of approving lomitapide in patients with homozygous familial hypercholesterolemia (HoFH). While... More
Aegerion (AEGR) Wins FDA Approval of Lomitapide in Lowering Cholesterol with HoFH Patients
October 17, 2012 3:52 PM EDTAegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), said to win FDA approval of lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in adult patients with Homozygous Familial Hypercholesterolemia (HoFH).... More
